• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    EVP & CFO Jain Rachit was granted 9,375 shares, increasing direct ownership by 34% to 37,097 units (SEC Form 4)

    5/22/25 4:23:22 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Jain Rachit

    (Last) (First) (Middle)
    C/O SCHRODINGER, INC.,
    1540 BROADWAY, 24TH FLOOR

    (Street)
    NEW YORK NY 10036

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Schrodinger, Inc. [ SDGR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP & CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    05/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 05/21/2025 A 9,375 A $0 37,097(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $20.51 05/21/2025 A 18,750 (3) 05/21/2035 Common Stock 18,750 $0 18,750 D
    Explanation of Responses:
    1. Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on May 21, 2025 and will vest in equal installments on each of July 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service with the company.
    2. Includes 35,530 unvested RSUs.
    3. The option was granted on May 21, 2025. The shares underlying the option are scheduled to vest with respect to 25% of the shares on May 16, 2025 and the remainder are scheduled to vest in equal monthly installments through May 16, 2029, subject to the Reporting Person's continued service with the company.
    Remarks:
    /s/ Donald Shum, as attorney-in-fact for Rachit Jain 05/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SDGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    12/19/2022$23.00Neutral
    Goldman
    3/1/2022$55.00Buy
    Citigroup
    11/19/2021$82.00 → $49.00Overweight → Equal-Weight
    Morgan Stanley
    11/19/2021$87.00Overweight
    Piper Sandler
    11/11/2021$80.00 → $52.00Buy → Neutral
    B of A Securities
    More analyst ratings

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      Schrödinger, Inc. (NASDAQ:SDGR) today reported that on May 21, 2025, the company granted restricted stock units (RSUs) with respect to 7,051 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs vest

      5/23/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger to Present at Jefferies Global Healthcare Conference

      Schrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference. The live presentation will take place on Wednesday, June 4, 2025 at 1:25 p.m. E.T. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotec

      5/22/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Announces CFO Appointment

      Richie Jain to succeed Geoffrey Porges as CFO Schrödinger (NASDAQ:SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial officer to pursue other opportunities. Richie Jain, who previously served as Schrödinger's senior vice president, strategic finance and head of corporate and business development, will succeed Geoffrey Porges as chief financial officer. Dr. Porges will serve as an advisor to the company through June 6, 2025, to ensure a smooth transition. "I want to thank Geoff for his commitment and service during his tenure. He strengthened the company's financial profile to support continued

      5/20/25 6:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

      Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

      3/10/25 8:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

      Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

      8/18/22 7:01:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Announces Appointment of Arun Oberoi to Board of Directors

      Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005040/en/Arun Oberoi was appointed to Schrödinger's Board of Directors in May 2022. He will serve on the company's Audit Committee. (Photo: Business Wire) "We are very pleased to welcome Arun to our Board," said Ramy Farid, Ph.D., president and chief executive officer of Schrödinger. "Aru

      5/19/22 7:00:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Schrodinger with a new price target

      Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00

      7/2/24 8:03:41 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KeyBanc Capital Markets initiated coverage on Schrodinger with a new price target

      KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00

      12/5/23 8:08:54 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Schrodinger with a new price target

      Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00

      5/5/23 8:17:18 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Financials

    Live finance-specific insights

    See more
    • Schrödinger Announces CFO Appointment

      Richie Jain to succeed Geoffrey Porges as CFO Schrödinger (NASDAQ:SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial officer to pursue other opportunities. Richie Jain, who previously served as Schrödinger's senior vice president, strategic finance and head of corporate and business development, will succeed Geoffrey Porges as chief financial officer. Dr. Porges will serve as an advisor to the company through June 6, 2025, to ensure a smooth transition. "I want to thank Geoff for his commitment and service during his tenure. He strengthened the company's financial profile to support continued

      5/20/25 6:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

      Company to host webcast to review data on Thursday, June 12, 2025 at 8:00 a.m. ET Schrödinger, Inc. (NASDAQ:SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safety, tolerability and anti-tumor activity of SGR-1505 in patients with relapsed/refractory B-cell malignancies. The poster presentations will incl

      5/14/25 9:30:00 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schrödinger Reports Strong First Quarter 2025 Financial Results

      First Quarter Total Revenue of $59.6 Million, Software Revenue of $48.8 Million Initial SGR-1505 Phase 1 Clinical Data to be Presented in June Maintains 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2025. "We are very pleased with Schrödinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "More broadly, the pharmaceutical industry and even regulator

      5/7/25 4:05:00 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    SEC Filings

    See more
    • SEC Form 8-K filed by Schrodinger Inc.

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      5/20/25 6:44:43 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Schrodinger Inc.

      8-K - Schrodinger, Inc. (0001490978) (Filer)

      5/19/25 4:16:35 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Schrodinger Inc.

      S-8 - Schrodinger, Inc. (0001490978) (Filer)

      5/7/25 4:25:07 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & CFO Jain Rachit was granted 9,375 shares, increasing direct ownership by 34% to 37,097 units (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      5/22/25 4:23:22 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Jain Rachit claimed ownership of 27,722 shares (SEC Form 3)

      3 - Schrodinger, Inc. (0001490978) (Issuer)

      5/22/25 4:22:41 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President of R&D, Therapeutics Akinsanya Karen exercised 16,723 shares at a strike of $3.16 and sold $419,570 worth of shares (16,723 units at $25.09) (SEC Form 4)

      4 - Schrodinger, Inc. (0001490978) (Issuer)

      4/15/25 4:31:21 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Schrodinger Inc.

      SC 13G - Schrodinger, Inc. (0001490978) (Subject)

      11/13/24 4:30:25 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      2/13/24 5:13:59 PM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

      SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

      1/23/24 11:52:31 AM ET
      $SDGR
      Biotechnology: Pharmaceutical Preparations
      Health Care